Biotech · Public company · Watertown, MA, US

Acrivon Therapeutics, Inc.

Ticker ACRV · SEC CIK 0001781174

Track this companyFree. Adds Acrivon Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials33 recruiting or active

Pipeline programs4From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline4

ACR-2316Phase 2 · Specific Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
ACR-368Phase 2 · Endometrial AdenocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
GemcitabinePhase 2 · Endometrial AdenocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
OncoSignaturePhase 2 · Endometrial AdenocarcinomaClinicalTrials.gov · fetched Nov 12, 2026

Study of ACR-2316 in Specific Advanced Solid TumorsPHASE1_PHASE2 · RECRUITING · started Oct 8, 2024ClinicalTrials.gov NCT06667141 · fetched Nov 12, 2026
A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCCPHASE2 · RECRUITING · started Sep 25, 2024ClinicalTrials.gov NCT06597565 · fetched Nov 12, 2026
A Phase 2 Study of ACR-368 in Endometrial AdenocarcinomaPHASE2 · RECRUITING · started Aug 29, 2022ClinicalTrials.gov NCT05548296 · fetched Nov 12, 2026